Weekly Dose 03
“No Better Than Antidepressants” Is Not The Story They Think It Is
TL;DR: The psychedelic field got its first serious scientific gut-punch this week. Here’s why the headline misses the point, and what actually matters.
FIELD UPDATES
💊 Big Pharma Just Spent $1.2 Billion on an MDMA Pill
Japanese pharma giant Otsuka has agreed to acquire Transcend Therapeutics for up to $1.225 billion — $700 million upfront. Transcend is developing methylone, an MDMA analogue designed to be easier to administer in clinical settings, as a once-weekly PTSD treatment currently entering Phase 3 trials. It follows AbbVie’s $1.2 billion acquisition of bretisilocin, a psilocybin-like compound, just six months ago.
When two separate pharmaceutical companies spend over a billion dollars each acquiring psychedelic drug candidates in the same six-month window, the question of whether this field is real has been answered. The question now is who profits from it — and whether the drugs that eventually reach patients will resemble the ones that made researchers excited in the first place.
🍄 Psychedelic Companies Are Paying YouTubers to Hype Unapproved Drugs
STAT News reported this week that several psychedelic biotech companies — including Helus Pharma (previously Cybin) and AtaiBeckley — have been paying third-party marketing firms to promote their experimental drugs on YouTube. One video claimed “100% patient improvement in Phase 2 trials” for a drug the FDA has not approved.
Marketing an unapproved drug directly to the public is legally murky and reputationally dangerous, particularly for a field that has spent years trying to earn the trust of regulators. The psychedelic industry’s biggest long-term threat isn’t a failed clinical trial. It’s a credibility collapse driven by hype outrunning evidence, and that collapse tends to happen fast.
🏛️ Seattle Just Made Psychedelics Its Lowest Enforcement Priority. Officially.
King County — which includes Seattle — passed a formal motion this week directing law enforcement to treat personal use and possession of naturally occurring psychedelics as among the lowest priorities for policing. The vote formalizes what local agencies were already doing in practice.
“Lowest priority” policies don’t make anything legal, they just redirect where police focus. But they’re spreading faster than any state legislature is moving, creating a quiet patchwork of de facto access across the Pacific Northwest. For many people, the practical difference between decriminalization and “lowest priority” is zero.
🎙️ Ibogaine Is Going Mainstream — One Conservative Evangelist at a Time
The Economist this week dedicated a 48-minute episode to Bryan Hubbard — the former Kentucky opioid commissioner who has spent the last three years trying to get state governments to fund ibogaine research. Starting in Kentucky (rejected), moving to Texas ($50 million secured), and now pushing nationally, Hubbard is the unlikely engine behind ibogaine’s political momentum.
Ibogaine is a powerful psychedelic derived from an African shrub with striking early results for opioid addiction and PTSD — and real cardiac risks that have kept it off the FDA’s radar. What makes Hubbard’s story interesting isn’t the drug. It’s the coalition: veterans, conservative politicians, and former governors who are building the case for one of the most dangerous psychedelics on the planet, in some of the reddest states in America.
UNDER THE MICROSCOPE
“No Better Than Antidepressants” Is Not The Story
A meta-analysis published this week in JAMA Psychiatry reviewed 24 psychedelic clinical trials and concluded that psychedelic-assisted therapy is “no more effective than traditional antidepressants.” The same week, a German government-funded trial of psilocybin for treatment-resistant depression failed its primary endpoint. Both findings landed hard in a field accustomed to good news.
The headline version of this story writes itself: the hype is catching up with the science. Psychedelics, it turns out, aren’t magic.
But the headline misses the actual question.
“No more effective than antidepressants” only sounds like bad news if the goal was to beat antidepressants in the general population. That was never the argument. The researchers and clinicians driving this field have been asking something more specific: do psychedelics work for people antidepressants have already failed?
Treatment-resistant depression — defined as depression that hasn’t responded to at least two standard antidepressant treatments — affects roughly 30% of the estimated 21 million Americans living with depression. For that population, “as effective as antidepressants” isn’t the benchmark. The benchmark is “works when nothing else has.” The JAMA meta-analysis doesn’t address that question, because most of the 24 trials it reviewed weren’t designed to.
There’s a second problem with how this week’s results are being read. Psychedelic-assisted therapy isn’t just a drug — it’s a drug plus a structured therapeutic experience, usually across multiple sessions with trained guides. The German trial that failed used a protocol. Whether it used the right protocol, with the right preparation, the right setting, and the right follow-up, is an open and meaningful question. Two trials using the same drug at the same dose can produce completely different outcomes depending on everything around the drug. That’s not a flaw unique to psychedelics — it’s a feature of how they work, and it makes them genuinely hard to study using the tools designed for antidepressants.
None of this means the skeptics are wrong. The field needed this. It needed a JAMA paper that pushed back, that introduced friction, that forced researchers to be more precise about what they’re actually claiming and for whom.
The question was never whether psychedelics are magic. It was whether they help the people nothing else has helped.
That question is still open.
DOSE OF THE WEEK
📖 Psychedelics and Cognitive Liberty: Reimagining Drug Policy Through the Prism of Human Rights — A 2016 academic paper by legal scholar Charlotte Walsh that makes a case most people in this space have never encountered: that the argument for psychedelics shouldn’t rest on medicine or safety, but on the fundamental right to control your own consciousness. Dense, short, and quietly radical.
Next week: the cognitive liberty argument in full — why the case for psychedelics that doesn’t mention depression or PTSD might be the most important one.
Stay curious. — DOSED